About this Journal Submit a Manuscript Table of Contents
Gastroenterology Research and Practice
Volume 2012 (2012), Article ID 420156, 9 pages
http://dx.doi.org/10.1155/2012/420156
Research Article

The Impact of Host Metabolic Factors on Treatment Outcome in Chronic Hepatitis C

14th Department of Internal Medicine, Hippokration General Hospital of Thessaloniki, Medical School of Aristotle University, 54642 Thessaloniki, Greece
2Department of Internal Medicine, Infectious Diseases Hospital of Thessaloniki, Thessaloniki, Greece
32nd Department of Internal Medicine, Hippokration General Hospital of Athens, University of Athens Medical School, 11527 Athens, Greece
4Division of Gastroenterology, Department of Internal Medicine, University Hospital of Patras, 26504 Rio Patras, Greece

Received 31 October 2011; Revised 23 January 2012; Accepted 1 February 2012

Academic Editor: Edoardo G. Giannini

Copyright © 2012 Savvidou Savvoula et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. P. Manns, J. G. McHutchison, S. C. Gordon, et al., “Peginterferon α-2b in combination with ribavirin compared to interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: results of a randomized trial,” The Lancet, vol. 358, pp. 958–965, 2001.
  2. M. W. Fried, M. L. Shiffman, K. Rajender Reddy et al., “Peginterferon α-2a plus ribavirin for chronic hepatitis C virus infection,” New England Journal of Medicine, vol. 347, no. 13, pp. 975–982, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. S. J. Hadziyannis, H. Sette, T. R. Morgan et al., “Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose,” Annals of Internal Medicine, vol. 140, no. 5, pp. 346–I67, 2004. View at Scopus
  4. P. Marcellin, T. Asselah, and N. Boyer, “Fibrosis and disease progression in hepatitis C,” Hepatology, vol. 36, no. 5, pp. S47–S56, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Negro, “Hepatitis C virus and liver steatosis: when fat is not beautiful,” Journal of Hepatology, vol. 40, no. 3, pp. 533–535, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. H. M. Patton, K. Patel, C. Behling et al., “The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients,” Journal of Hepatology, vol. 40, no. 3, pp. 484–490, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Lonardo, P. Loria, L. E. Adinolfi, N. Carulli, and G. Ruggiero, “Hepatitis C and steatosis: a reappraisal,” Journal of Viral Hepatitis, vol. 13, no. 2, pp. 73–80, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Lonardo, L. E. Adinolfi, P. Loria, N. Carulli, G. Ruggiero, and C. P. Day, “Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease,” Gastroenterology, vol. 126, no. 2, pp. 586–597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  9. L. E. Adinolfi, E. Durante-Mangoni, R. Zampino, and G. Ruggiero, “Review article: hepatitis C virus-associated steatosis-pathogenic mechanisms and clinical implications,” Alimentary Pharmacology and Therapeutics, vol. 22, no. 2, pp. 52–55, 2005. View at Scopus
  10. T. Poynard, V. Ratziu, J. McHutchison et al., “Effect of treatment with peginterferon or interferon α-2b and ribavirin on steatosis in patients infected with hepatitis C,” Hepatology, vol. 38, no. 1, pp. 75–85, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. A. R. El-Zayadi, “Hepatic steatosis: a benign disease or a silent killer,” World Journal of Gastroenterology, vol. 14, no. 26, pp. 4120–4126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. T. Asselah, L. Rubbia-Brandt, P. Marcellin, and F. Negro, “Steatosis in chronic hepatitis C: why does it really matter?” Gut, vol. 55, no. 1, pp. 123–130, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. L. Castera, P. Chouteau, C. Hezode, E. S. Zafrani, D. Dhumeaux, and J. M. Pawlotsky, “Hepatitis C virus-induced hepatocellular steatosis,” American Journal of Gastroenterology, vol. 100, no. 3, pp. 711–715, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Harrison, E. M. Brunt, R. A. Qazi et al., “Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C,” Clinical Gastroenterology and Hepatology, vol. 3, no. 6, pp. 604–609, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Sanyal, M. J. Contos, R. K. Sterling et al., “Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome,” American Journal of Gastroenterology, vol. 98, no. 9, pp. 2064–2071, 2003. View at Publisher · View at Google Scholar · View at Scopus
  16. L. Rubbia-Brandt, R. Quadri, K. Abid et al., “Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3,” Journal of Hepatology, vol. 33, no. 1, pp. 106–115, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Kumar, G. C. Farrell, C. Fung, and J. George, “Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response,” Hepatology, vol. 36, no. 5, pp. 1266–1272, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. S. T. Shi, S. J. Polyak, H. Tu, D. R. Taylor, D. R. Gretch, and M. M. C. Lai, “Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins,” Virology, vol. 292, no. 2, pp. 198–210, 2002. View at Publisher · View at Google Scholar · View at Scopus
  19. L. Castera, C. Hezode, F. Roudot-Thoraval et al., “Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis,” Gut, vol. 53, no. 3, pp. 420–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Moriya, H. Yotsuyanagi, Y. Shintani et al., “Hepatitis C virus core protein induces hepatic steatosis in transgenic mice,” Journal of General Virology, vol. 78, no. 7, pp. 1527–1531, 1997. View at Scopus
  21. F. Negro and A. J. Sanyal, “Hepatitis C virus, steatosis and lipid abnormalities: clinical and pathogenic data,” Liver International, vol. 29, no. 2, pp. 26–37, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Soresi, S. Tripi, V. Franco et al., “Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis,” Liver International, vol. 26, no. 9, pp. 1119–1125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. K. C. Thomopoulos, G. J. Theocharis, A. C. Tsamantas et al., “Liver steatosis is an independent risk factor for treatment failure in patients with chronic hepatitis C,” European Journal of Gastroenterology and Hepatology, vol. 17, no. 2, pp. 149–153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Yaginuma, K. Ikejima, K. Okumura et al., “Hepatic steatosis is a predictor of poor response to interferon α-2b and ribavirin combination therapy in Japanese patients with chronic hepatitis C,” Hepatology Research, vol. 35, no. 1, pp. 19–25, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. C. Y. Dai, J. F. Huang, M. Y. Hsieh et al., “Insulin resistance predicts response to peginterferon-α/ribavirin combination therapy in chronic hepatitis C patients,” Journal of Hepatology, vol. 50, no. 4, pp. 712–718, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. B. L. Bressler, M. Guindi, G. Tomlinson, and J. Heathcote, “High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C,” Hepatology, vol. 38, no. 3, pp. 639–644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. M. J. Walsh, J. R. Jonsson, M. M. Richardson et al., “Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signaling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1,” Gut, vol. 55, no. 4, pp. 529–535, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Romero-Gomez, M. Del Mar Viloria, R. J. Andrade et al., “Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients,” Gastroenterology, vol. 128, no. 3, pp. 636–641, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. R. D'Souza, C. A. Sabin, and G. R. Foster, “Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy,” American Journal of Gastroenterology, vol. 100, no. 7, pp. 1509–1515, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Zekry, J. G. McHutchison, and A. M. Diehl, “Insulin resistance and steatosis in hepatitis C virus infection,” Gut, vol. 54, no. 7, pp. 903–906, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Bedossa and T. Poynard, “An algorithm for the grading of activity in chronic hepatitis C. The METAVIR cooperative study group,” Hepatology, vol. 24, pp. 289–293, 1996.
  32. E. M. Brunt, “Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond,” Hepatology, vol. 31, no. 1, pp. 241–246, 2000. View at Scopus
  33. E. M. Brunt, C. G. Janney, A. M. Di Bisceglie, B. A. Neuschwander-Tetri, and B. R. Bacon, “Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions,” American Journal of Gastroenterology, vol. 94, no. 9, pp. 2467–2474, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. D. B. Strader, T. Wright, D. L. Thomas, and L. B. Seeff, “Diagnosis, management, and treatment of hepatitis C,” Hepatology, vol. 39, no. 4, pp. 1147–1171, 2004. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Khattab, M. Eslam, M. A. Sharwae, M. Shatat, A. Ali, and L. Hamdy, “Insulin resistance predicts rapid virologic response to peginterferon/ribavirin combination therapy in hepatitis C genotype 4 patients,” American Journal of Gastroenterology, vol. 105, no. 9, pp. 1970–1977, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. H. El Makhzangy, G. Esmat, M. Said et al., “Response to pegylated interferon α-2a and ribavirin in chronic hepatitis C genotype 4,” Journal of Medical Virology, vol. 81, no. 9, pp. 1576–1583, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. G. López-Alonso, M. Agreda, M. J. Devesa et al., “Results of the treatment of chronic hepatitis C genotype 4: a comparative analysis with genotype 1,” Revista Espanola de Enfermedades Digestivas, vol. 100, no. 4, pp. 208–211, 2008. View at Scopus
  38. D. Roulot, V. Bourcier, V. Grando et al., “Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection,” Journal of Viral Hepatitis, vol. 14, no. 7, pp. 460–467, 2007. View at Publisher · View at Google Scholar
  39. S. Savvidou, I. Goulis, D. Chrysagis, et al., “Patients with genotype 4 HCV infection respond worse to 48week combination therapy with peginterferon α plus ribavirin when compared to patients with genotype 1: the greek experience,” Hepatology, vol. 52, supplement 1, p. 792A, 2010.
  40. K. R. Reddy, S. Govindarajan, P. Marcellin et al., “Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon α-2a plus ribavirin,” Journal of Viral Hepatitis, vol. 15, no. 2, pp. 129–136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. C. A. L. Matos, R. M. Perez, M. S. Pacheco et al., “Steatosis in chronic hepatitis C: relationship to the virus and host risk factors,” Journal of Gastroenterology and Hepatology, vol. 21, no. 8, pp. 1236–1239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Romero-Gomez, V. M. Castellano-Megias, L. Grande et al., “Serum leptin levels correlate with hepatic steatosis in chronic hepatitis C,” American Journal of Gastroenterology, vol. 98, no. 5, pp. 1135–1141, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. L. E. Adinolfi, M. Gambardella, A. Andreana, M. F. Tripodi, R. Utili, and G. Ruggiero, “Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity,” Hepatology, vol. 33, no. 6, pp. 1358–1364, 2001. View at Publisher · View at Google Scholar · View at Scopus
  44. L. Fartoux, A. Poujol-Robert, J. Guéchot, D. Wendum, R. Poupon, and L. Serfaty, “Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C,” Gut, vol. 54, no. 7, pp. 1003–1008, 2005. View at Publisher · View at Google Scholar · View at Scopus